RASSF1A is a major tumor suppressor gene located at 3p21.3. We investigated the role of aberrant promoter region hypermethylation of RASSF1A in a large series of adult gliomas. RASSF1A was frequently methylated in both primary tumors (36/63; 57%) and tumor cell lines (7/7; 100%). Hypermethylation of RASSF1A in glioma cell lines correlated with loss of expression and treatment with a demethylating agentreactivated RASSF1A gene expression. Furthermore, reexpression of RASSF1A suppressed the growth of glioma cell line H4 in vitro. Next, we investigated whether other members of the RASSF gene family were also inactivated by methylation. NORE1B and RASSF3 were not methylated in gliomas, while NORE1A and RASSF5/ AD037 demonstrated methylation in glioma cell lines but not in primary tumors. We then investigated the methylation status of three other candidate 3p21.3 tumor suppressor genes. CACNA2D2 and SEMA3B were not frequently methylated, but the BLU gene located just centromeric to RASSF1 was frequently methylated in glioma cell lines (7/7) and in 80% (35/44) of glioma tumors. In these tumor cell lines, BLU expression was restored after treatment with a demethylating agent. Loss of BLU gene expression in glioma tumors correlated with BLU methylation. There was no association between RASSF1A and BLU methylation. RASSF1A methylation increased with tumor grade, while BLU methylation was seen at similar frequencies in all grades. Our data implicate RASSF1A and BLU promoter methylation in the pathogenesis of adult gliomas, while other RASSF family members and CACNA2D2 and SEMA3B appear to have only minor roles. In addition, RASSF1A and BLU methylation appear to be independent and specific events and not due to region-wide changes in DNA methylation.
RASSF1A is a major tumor suppressor gene located at 3p21.3. We investigated the role of aberrant promoter region hypermethylation of RASSF1A in a large series of adult gliomas. RASSF1A was frequently methylated in both primary tumors (36/63; 57%) and tumor cell lines (7/7; 100%). Hypermethylation of RASSF1A in glioma cell lines correlated with loss of expression and treatment with a demethylating agentreactivated RASSF1A gene expression. Furthermore, reexpression of RASSF1A suppressed the growth of glioma cell line H4 in vitro. Next, we investigated whether other members of the RASSF gene family were also inactivated by methylation. NORE1B and RASSF3 were not methylated in gliomas, while NORE1A and RASSF5/ AD037 demonstrated methylation in glioma cell lines but not in primary tumors. We then investigated the methylation status of three other candidate 3p21.3 tumor suppressor genes. CACNA2D2 and SEMA3B were not frequently methylated, but the BLU gene located just centromeric to RASSF1 was frequently methylated in glioma cell lines (7/7) and in 80% (35/44) of glioma tumors. In these tumor cell lines, BLU expression was restored after treatment with a demethylating agent. Loss of BLU gene expression in glioma tumors correlated with BLU methylation. There was no association between RASSF1A and BLU methylation. RASSF1A methylation increased with tumor grade, while BLU methylation was seen at similar frequencies in all grades. Our data implicate RASSF1A and BLU promoter methylation in the pathogenesis of adult gliomas, while other RASSF family members and CACNA2D2 and SEMA3B appear to have only minor roles. In addition, RASSF1A and BLU methylation appear to be independent and Introduction Gliomas are a heterogenous group of primary brain tumors that may be divided into four grades on the basis of their histology and prognosis. Patients with the most malignant gliomas (grade 4), also known as glioblastoma multiforme (GBM), have a mean survival of about a year. Patients with anaplastic gliomas (grade 3) survive for 2-3 years and those with grade 2 gliomas survive for 10-15 years (Holland 2001; Louis et al., 2002) .
Genetic analysis of gliomas has identified various cytogenetic and molecular genetic changes, and in some cases these findings correlate with clinical grade (reviewed in Holland 2001; Louis et al., 2002) . Methylation of CG dinucleotides in the promoter region of tumor suppressor genes (TSGs) producing transcriptional silencing is a major mechanism of TSG inactivation in many human cancers. In this report, we undertook methylation analysis of 12 genes in a large series of adult gliomas and glioma cell lines.
The genes analysed include RASSF1 family members (RASSF1A, NORE1, RASSF3 and RASSF/AD037). RASSF1A is a major TSG located within the critical 120 kb interval at 3p21.3, defined by overlapping homozygous deletions in lung and breast tumor cell lines (Lerman and Minna, 2000) . It is a novel TSG in that it is frequently inactivated in many types of human cancers by aberrant promoter methylation (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001) , while somatic inactivating mutations are a rare event (reviewed in Pfeifer et al., 2002) . The gene encodes two major isoforms that are produced by alternative promoter selection and alternative messenger RNA splicing. The longer isoform known as RASSF1A (340 amino acids, 39 kD a peptide) contains a predicted Nterminal diacylglycerol-binding (DAG) domain and a Cterminal predicted RAS-association domain. The shorter isoform known as RASSF1C (270 amino acids, 32 kDa peptide) has a different N-terminus that lacks the DAG domain, but has a similar C-terminus containing a predicted RAS association domain. Exogenous expression of RASSF1A in cell lines lacking expression caused suppression of the malignant phenotype both in in vitro and in vivo assays. RASSF1A protein function is being actively investigated, and recently it was demonstrated that RASSF1A blocks cell cycle progression and suppresses cyclin D1 accumulation (Shivakumar et al., 2002; Agathanggelou et al., 2003a,b) .
Using in silico analysis followed by cloning and sequencing, we and others have identified three further members of the RASSF gene family containing a ras association domain (RA). NORE1 is located at 1q32.1, it has two major isoforms, NORE1A and NORE1B. Both isoforms have separate CpG islands spanning their first exons. NORE1A contains a predicted DAG domain and a predicted RAS association domain, while NORE1B contains only the predicted RAS association domain. We recently demonstrated that NORE1A but not NORE1B promoter region CpG island was methylated in breast, lung, colorectal and kidney tumor cell lines; furthermore, NORE1A expression in tumor cell lines was reactivated after treatment with a demethylating agent. In primary tumors, NORE1A was found to be methylated in 24% of NSCLC but in 0% of SCLCs (Hesson et al., 2003) . No somatic inactivating mutations were found in lung cancers. RASSF1A heterodimerizes with the mouse Nore1 gene, a known ras effector (OrtizVega et al., 2002) . Recently, both NORE1 and RASSF1A have been shown to associate with the proapoptotic kinase MST1 .
RASSF3 was recently described by Tommasi et al. (2002) ; it is located at 12q14.1 and also contains a RAS association domain at the C-terminus. It is expressed in many normal tissues. Tommasi et al found no inactivating mutations in the coding region in lung and breast tumors, but methylation status of RASSF3 was not analysed.
RASSF5/AD037 was recently identified and characterized by us. It resides at 10p11.21 and produces a protein of 321 amino acids containing a RAS association domain in its carboxy terminus. RASSF5 has a CpG island spanning the first exon. No inactivating mutations were found in lung cancers; however, the CpG island is hypermethylated in breast, lung, colorectal and kidney tumor cell lines and in primary lung and breast tumors. Furthermore in primary tumors and tumor cell lines, loss of expression correlated with RASSF5 methylation (Hesson and Latif, personal communication) .
In this report, we undertook systematic analysis of RASSF family members in a large series of adult glioma tumors and cell lines. Furthermore, we determined methylation status of three other genes residing in the critical 3p21.3 region, namely, CACNA2D2, BLU and SEMA3B in the above series of gliomas. In addition, the same series of gliomas were analysed for five (CASP8, DAPK1, MGMT, GSTP1, CLDN7) further genes that are known to play a part in tumorigenesis.
Results

RASSF1A, NORE1, RASSF3 and RASSF5 methylation analysis
We utilized a methylation-sensitive PCR (MSP) assay described previously (Honorio et al., 2003a, b) to determine the hypermethylation status of RASSF1A promoter-associated CpG island. RASSF1A was completely methylated in five glioma cell lines and partially methylated in two (7/7; 100%) ( Figure 1a) . In primary glioma tumors, RASSF1A was methylated in 36/63 (57%) (Table 1, Figure 1b ). RASSF1A methylation increased with tumor grade (4/10, 40% grade II; 8/15, 53% grade III; 24/38, 63% IV), although it was not statistically significant. None of the DNA isolated from normal adult brains demonstrated any methylation of the RASSF1A 5 0 CpG island. RASSF1A expression was restored in six glioma cell lines (five of which were completely methylated) after treatment with 5-aza-2-deoxycytidine ( Figure 2) .
For 20 GBM, corresponding blood DNA was available for loss of heterozygosity (LOH) analysis. Using microsatellite markers D3S1568 and D3S3667 (both located in the 3p21.3 region), we did not find any evidence of LOH at D3S1568 in 15 informative cases, while D3S3667 demonstrated allele loss in one of 16 informative pairs.
NORE1A was methylated in 3/7 (partially in two and completely methylated in one) of glioma cell lines, but in none (0/20) of primary glioma tumors. NORE1B 5 0 CpG island was found to be unmethylated in cell lines (0/7); therefore, primary glioma tumors were not analysed. Similarly, 5
0 CpG island associated with RASSF3 was found to be unmethylated in all glioma cell lines analysed (0/6). While RASSF5 5 0 CpG island was partially methylated in 3/7 of glioma cell lines, none of the tumors were methylated (0/20). These data are summarized in Table 1 and Figure 1 .
Methylation analysis of 5
0 CpG island associated with three further genes located at 3p21.3
Recently, we have demonstrated that a 5 0 CpG island associated with a candidate suppressor gene (BLU) located immediately centromeric to RASSF1 locus (Figure 3 ) is frequently hypermethylated in neuroblastomas and less frequently in lung cancer. This methylation correlates with loss of gene expression, and the expression is restored after treatment with demethylating agents . We have now analysed methylation status of BLU in the above series of glioma cell lines and tumors using an MSP assay described earlier. BLU was found to be completely methylated in two glioma cell lines and partially methylated in five (Figure 4a ). Expression of BLU was absent or downregulated in glioma cell lines showing methylation and expression was restored after treatment of two glioma tumor lines with 5-aza-2-deoxycytidine (Figure 4b and c) . In primary tumors, BLU was found to be frequently and heavily methylated (35/44; 80%) since many tumors showed only the methylated alleles (Figure 4d ). Using quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR), we demonstrated that loss of BLU gene expression correlated with BLU methylation in glioma tumors (Figure 4e) . None of the DNA from 20 corresponding lymphocytes or from normal adult brain was found to be methylated for this CpG island, indicating tumorspecific methylation. There was no association between BLU and RASSF1A methylation in this series of gliomas (P ¼ 0.45).
The CACNA2D2 gene located 162.7 kb centromeric of RASSF1 locus ( Figure 3 ) is a new member of the Ca(2 þ ) channel complex (Gao and Minna, personal communication; Lerman and Minna, 2000) . Majority of NSCLC cell lines show loss of CACNA2D2 gene expression. We have recently demonstrated that this loss of gene expression (both at RNA and protein levels) correlates with hypermethylation of a CpG island in the promoter of CACNA2D2 in NSCLC (Gao and Minna, personal communication). It has recently been shown that overexpression of CACNA2D2 induced apoptosis in NSCLC lines (Carboni et al., 2003) . Using direct sequencing of bisulfite-modified DNA (see materials and methods for primer sequence), we analysed part of the 5 0 CpG island of CACNA2D2 in glioma cell lines. Four of the six lines were partially methylated, but only one of 24 primary glioma tumors was methylated.
SEMA3B located 72 kb telomeric of the RASSF1 locus ( Figure 3 ) is a member of the semaphorin gene family comprised of secreted and membrane-associated proteins that contribute to axonal path finding during neural development. SEMA3B has recently been shown ND, not determined. In this study, glioma tumors were analysed only if frequent methylation was found in glioma tumor cell lines Figure 2 Expression of RASSF1A in methylated glioma tumor cell lines before and after treatment with the demethylating agent 5 0 aza-2-deoxycytidine. RASSF1A expression is vastly upregulated following 5 0 -aza-2-deoxycytidine treatment ( þ ) in methylated glioma cell lines. RASSF1F (another isoform of the RASSF1 gene) is also upregulated showing that transcription of this isoform is controlled via the same promoter region. GAPDH was used as a positive control to ensure RNA integrity and equal loading Figure 1 (a) The methylation status of the RASSF family members RASSF1A, NORE1A, NORE1B, RASSF3 and RASSF5 in glioma tumor cell lines. RASSF1A and NORE1A methylation status was determined using MSP. NORE1B, RASSF3 and RASSF5 methylation was determined using the COBRA method (TaqI/BstUI digestion and direct sequencing). The undigested PCR product and TaqI-digested PCR product are shown in the NORE1B and RASSF3 diagrams. RASSF5 TaqI-and BstUIdigested PCR products are also shown. Frequent methylation was observed in RASSF1A (7/7), NORE1A (3/7) and partial methylation of three lines was observed for RASSF5 (3/7). N1, N2 and N3 represent the DNA from three individual normal brain tissues. No methylation of the RASSF3 and NORE1B CpG islands was observed in any of the glioma tumor cell lines analysed. (b) The methylation status of RASSF1A, NORE1A and RASSF5 in glioma primary tumors using MSP (RASSF1A and NORE1A) and COBRA (RASSF5). Frequent RASSF1A methylation was observed in glioma tumors, whereas NORE1A and RASSF5 methylation was not observed in any tumors analysed. U343 and U373 were included as RASSF5 methylation positive controls. PCR ¼ undigested PCR product; T ¼ TaqI digest; B ¼ BstUI digest. Sss1 in vitro methylated normal blood DNA was used as a positive control Epigenetic inactivation of RASSF1A and BLU L Hesson et al to inhibit lung cancer cell growth and re-expressioninduced apoptosis in NSCLC cell lines (Tomizawa et al., 2001) . SEMA3B was found to be methylated in NSCLC tumor cell lines and primary tumors (Tomizawa et al., 2001; Kuroki et al., 2003) . By direct sequencing of bisulfite-modified DNA with appropriate primers Figure 3 Schematic representation of the 3p21.31 homozygously deleted region and the location and distances between four candidate genes analysed. Previously, the 3p21.3 region was implicated in lung cancer by the identification of three independent lung cancer homozygous deletions (Lerman and Minna, 2000) represented by the 370 kb deletion region (wavy lines; NCI-H1450, NCI-H740 and GLC20). Identification of a breast cancer homozygous deletion (HCC1500) refined the candidate region to 120 kb. The causative TSG/ TSGs could, however, reside in the minimal 120 kb indicated by the breast cancer homozygous deletion or the additional 250 kb indicated by the lung cancer homozygous deletions. Several promising candidates have been identified and their involvement in several other cancers has been recently established. We undertook epigenetic analysis of four such candidates to assess their involvement in gliomagenesis; SEMA3B (NM_004636), RASSF1A (NM_007182), BLU (NM_015896) and CACNA2D2 (NM_006030). Distances between genes were calculated from their transcriptional start sites as indicated by the respective Genbank accession numbers. LOH status was determined using the nearest flanking polymorphic loci indicated by two asterisks. D3S1568 is located within intron 2 of the gene CACNA2D2. D3S3667 is located within intron 5 of the gene RBM6 (B275 kb upstream of the gene SEMA3B) CpG island to be partially methylated in 1/7 glioma cell lines. Since the methylation frequency was low in glioma tumor lines, primary tumors were not analysed.
Methylation analysis of five other genes known to play roles in tumorigenesis
We went onto analyse the same large series of glioma tumors and cell lines for methylation in CASP8, DAPK1, MGMT, GSTP1 and CLDN7 genes. Previously, we and others had described frequent methylation of CASP8 in neuroblastomas (Teitz et al., 2000; Astuti et al., 2001) . Recently, CASP8 methylation has been described in other pediatric tumors and in lung cancer (Harada et al., 2002; Shivapurkar et al., 2002) . We used an MSP assay to determine methylation status of CASP8 in glioma cell lines. None of the glioma cell lines (0/7) were found to be methylated, similarly no glioma cell line was methylated for DAPK1 (0/7) and GSTP1 (0/7) (Figure 5a ). MGMT was frequently methylated in glioma cell lines (completely methylated in three, partially methylated in three and unmethylated in one) and tumors (10/18; 56%). None of the DNA from normal adult brain was methylated for MGMT (Figure 5a, b) .
Claudin-7 (CLDN-7) is a member of a large gene family (20 members so far) (Mitic et al., 2000) located at 17p13.1. Claudins are transmembrane proteins that seal tight junctions and are critical for maintaining cell-tocell adhesion. Recently, Claudin-7 expression was found to be lower in breast carcinomas than in normal breast epithelium (Kominsky et al., 2003) . An MSP assay was developed to determine the methylation status of the 5 0 CpG island associated with CLDN-7. Three out of three breast tumor lines analysed were found to be methylated and gene expression was restored in these tumor lines after treatment with 5-aza-dC. However, no methylation was detected in five invasive ductal carcinomas (Kominsky et al., 2003) . Claudins have tissue-specific expression patterns. CLDN-7 is well expressed in brain, heart, liver, pancreas, prostate, kidney and lung. Hence, we utilized the MSP primers described in the above reference to determine the status of the 5 0 CpG island associated with CLDN-7 in gliomas. CLDN-7 was methylated in four of six glioma cell lines (two partial and two completely methylated), but in only 2 of 45 glioma tumors (Figure 5a, b) . Exogenous expression of RASSF1A has been shown to decrease in vitro colony-formation ability in lung tumor cell lines exhibiting RASSF1A hypermethylation and loss of expression (Dammann et al., 2000; Burbee et al., 2001) . Wild-type RASSF1A in the pCMVHA-tagged construct or empty pCMVHA construct were transfected into glioma cell line H4 (completely methylated for and lacking expression of RASSF1A). Using a colony-formation assay, we show that re-expression of RASSF1A significantly (P ¼ 0.028) reduces colony-formation ability by approximately 64% (Figure 6 ). This effect was consistent through three independent experiments.
Discussion
To our knowledge, this is the first report describing systematic epigenetic analysis of members of the RASSF gene family in any tumor type. Our data indicate that RASSF1A is frequently inactivated by promoter region hypermethylation in adult gliomas and promoter hypermethylation is associated with loss of gene expression.
Furthermore, exogenous expression of RASSF1A decreased in vitro colony formation. RASSF3 is not methylated in glioma tumor cell lines, while NORE1A and RASSF5 are frequently methylated in glioma tumor cell lines but not in primary tumors. Hence, NORE1A and RASSF5 may play a role in very late gliomagenesis. We also demonstrated that allele loss at 3p21.3 in gliomas was a rare event. Although we did not analyse for RASSF1A somatic mutations in our series of adult gliomas, previous studies in various tumor types have demonstrated that inactivation of RASSF1A by somatic mutations is a very rare event. It is clear that majority of glioma tumor cell lines we analysed exhibit only methylated alleles. Even though the glioma tumors used in this study were not microdissected, several tumors exhibited only methylated alleles. Hence, its seems likely that major mechanism of RASSF1A inactivation in adult gliomas is via biallelic promoter region hypermethylation as has been recently demonstrated for RASSF1A methylation in medulloblastomas (Lusher et al., 2002) .
The critical region at 3p21.3 where the RASSF1 gene is located was delineated by findings of overlapping homozygous deletions in lung and breast cancer cell . We now demonstrate that BLU is frequently methylated in adult gliomas, and BLU expression can be restored after treating methylated glioma cell lines with a demethylating agent. BLU methylation in primary tumors also correlated with a reduction in BLU expression. In two tumors where only the methylated allele was detected, BLU expression was markedly downregulated relative to unmethylated tumors. The residual expression in these two tumors may be due to normal infiltrating lymphocytes since the tumors were not microdissected. As was the case in neuroblastomas, there was no association between BLU and RASSF1A methylation in adult gliomas, suggesting that inactivation of BLU is an independent event and not the result of methylation of the 3p21.3 region in these tumor types. In fact, in gliomas methylation of the BLU gene was more frequent than RASSF1A methylation (P ¼ 0.022). Furthermore, many glioma tumors and tumor lines exhibited only methylated alleles, indicating that epigenetic inactivation of BLU plays an important role in gliomas. We demonstrated high frequency of BLU methylation in all grades of gliomas, while RASSF1A methylation frequency increased with tumor grade. In a recent study, Liu et al. (2003) also reported that 74% of nasopharyngeal carcinoma underwent BLU methylation and that 78% of the primary tumors demonstrated absent or reduced BLU expression. CACNA2D2 is a large gene encompassing 141 kb of genomic DNA, it lies centromeric of BLU and RASSF1 loci and contains a large 5 0 CpG island. Using direct sequencing of bisulfite-modified DNA, we demonstrated that four of six glioma cell lines were partially methylated, but in primary glioma tumors methylation of CACNA2D2 was a rare event.
We have recently demonstrated that the axon guidance molecule SLIT2 is frequently methylated in lung, breast, colorectal and glioma tumors (Dallol et al., 2002 (Dallol et al., , 2003a . Semaphorins comprise another large family of proteins that play important roles in axonal pathfinding during neural development. SEMA3B is located 72 kb telomeric of RASSF1 locus at 3p21.3. SEMA3B shows loss of expression in many NSCLC cell lines. There have been two previous studies demonstrating hypermethylation of the 5 0 CpG island associated with SEM3B gene in NSCLC cancer cell lines and this hypermetylation correlated with loss of gene expression (Tomizawa et al., 2001) . Recently, SEMA3B was demonstrated to be methylated in primary non-smallcell lung tumors (Kuroki et al., 2003) . By direct sequencing of bisulfite-modified DNA, only one of Epigenetic inactivation of RASSF1A and BLU L Hesson et al seven glioma cell lines was found to be partially methylated for SEMA3B. Our CACNA2D2 and SE-MA3B data further support the importance of RASS-F1A and BLU methylation in gliomas in that it is not a regional methylation effect.
We also demonstrated frequent epigenetic inactivation of MGMT gene in glioma tumors, while CASP8, DAPK1, GSTP1 and CLDN7 methylation was a rare event. Previously we had analysed the same series of gliomas for p16 (0/18) and SLIT2 (37/63; 59%) methylation . There was no correlation between RASSF1A, BLU or SLIT2 methylation status in this series of tumors. Our data also highlight the importance of analysing primary tumors since frequent methylation in tumor cell lines does not necessary mean frequent in vivo methylation (in primary tumors). For example, NORE1A, RASSF5, CAC-NA2D2 and CLDN7 were frequently methylated in glioma cell lines but rarely in tumors. This is a comprehensive methylation profile of a large series of well-characterized gliomas, suggesting that epigenetic inactivation of specific genes may be important in glioma development. Our data indicate that not only RASSF1A but also the BLU gene residing just centromeric of RASSF1 is frequently inactivated by promoter region hypermethylation in gliomas and that in many cases it may be biallelic hypermethylation. Our data warrant further genetic/epigenetic and functional analysis of this novel gene (BLU) in order to understand its role in tumorigenesis. The elucidation of the functions of the RASSF1A and BLU proteins may lead to new strategies for molecular targeted therapy for certain cancers.
Materials and methods
Tumor samples
A total of seven glioblastoma tumor cell lines (U87, A172, U343, U373, T17, H4 and Hs683) and 65 primary glioma tumors (10 grade II, 15 grade III and 40 grade IV) were analysed for promoter region methylation. All grade II and III gliomas are oligodendrogliomas. In addition, six normal adult brain samples were also analysed for promoter hypermethylation. These were designated N1, N2, N3, N4, N5 and N6. The typical normal brains collected are those from autopsy for whatever reason (e.g. from auto accidents) and are examined by a neuropathologist to document that the brain is normal.
Sodium bisulfite modification
Sodium bisulfite modification was performed as described previously . Briefly, 0.5-1.0 mg of genomic DNA was denatured in 0.3 M NaOH for 15 min at 371C. Unmethylated cytosine residues were then sulphonated by incubation in 3.12 M sodium bisulfite (pH5.0) (Sigma) and 5 mM hydroquinone (Sigma) in a thermocycler (hybaid Omn-E) for 15 s at 991C and 15 min at 501C for 20 cycles. Sulphonated DNA was then recovered using the Wizard DNA cleanup system (Promega), according to the manufacturer's instructions. The DNA was desulphonated by addition of 0.3 M NaOH for 10 min at room temperature. The converted DNA was then ethanol precipitated and resuspended in 50 ml water.
MSP
The promoter methylation status of RASSF1A, NORE1A, BLU, MGMT, CASP8, CLDN7, DAPK1 and GSTP1 were determined using MSP (Herman et al., 1996) . The conditions and primers used for the MSP reactions are described in Table 2 . For each gene, two sets of primers were used that distinguish between methylated and unmethylated DNA sequences. All reactions (including MSP and COBRA) were performed on a GeneAmp 9700 thermocycler (Perkin Elmer) and with HotStar Taq DNA polymerase (Qiagen). SssI in vitro methylated (IVM) normal blood DNA was used as a positive control.
Combined bisulfite restriction analysis (CoBRA) and direct sequencing
The promoter methylation status of RASSF3, RASSF5, NORE1B and CACNA2D2 were determined using the COBRA method followed by direct sequencing to confirm methylation status and ascertain the extent of methylation, if present. SEMA3B was directly sequenced without prior assay using restriction enzymes. All primers and a summary of PCR conditions used for methylation analysis are listed in Table 2 . The assays used to determine methylation status at the CACNA2D2 and RASSF3 CpG islands were novel assays. For RASSF3, primers were designed to amplify the putative promoter region at À3514À44 bp relative to the transcription start point of EST BU182700 (PromoterInspector at www.genomatix.de). The region examined for methylation was also within a CpG island located À6334 þ 482 bp relative to the transcription start point of EST BU182700 (CpGplot at www.ebi.ac.uk). This CpG island was 1116 bp in length with an ObsExp of 1.05 and a percentage CG of 74.1% (CpGreport at www.ebi.ac.uk). The conditions and primers were as follows; initial denaturation for 10 min at 951C, followed by 25 cycles of 1 min at 941C, 1 min at 541C and 2 min at 741C with a final extension for 10 min at 721C using the primers RASSF3 F 5 0 -TTGAGGAAGYGATTYGAGTATAGTTT-TAGT-3 0 and RASSF3 R 5 0 -CAAAAACACRTAAAAA-CAAAAAACRCRAACTAA-3 0 (where Y ¼ C or T and R ¼ A or G to allow unbiased PCR amplification with regards to methylation status). The reaction volume of 20 ml contained 40 ng bisulfite-modified DNA, 1.5 mM MgCl 2 , 0.25 mM dNTPs, 1 mM each primer and 0.5 U HotStar Taq (Qiagen). A measure of 1 ml of this reaction was then used in a seminested PCR reaction (50 mls) using RASSF3 F (described above) and RASSF3 RN 5 0 -CCACTCACTTATTAAC-CRAAACRAAACTTA-3 0 and the same PCR program but with 1 U HotStar Taq, 0.4 mM each primer and an annealing temperature of 561C. This produced a 533 bp product.
CACNA2D2 promoter
The sequence AF042794 submitted to Genbank corresponds to the genomic sequence encompassing exon 1 of CACNA2D2 and has previously been shown to have promoter activity (Gao and Minna, personal communication) . Primers were designed to amplify the promoter region at À3774À9 bp relative to the transcription start point of NM_006030. The region examined for methylation was also within a CpG island located À9334 þ 960 bp relative to the transcription start point of NM_006030 (CpGplot at www.ebi.ac.uk). This CpG island was 1893 bp in length with an ObsExp of 1.09 and a percentage CG of 69.65% (CpGreport at www.ebi.ac.uk). The primers used to determine the methylation status of the CACNA2D2 promoter were CACNA2D2 F 5 0 -TTATTATTAAATTTGT-GATTTTAGGTTTTAAGTT-3 0 and CACNA2D2 R 5 0 -TCCCTACAACRCTAACTCCAAA-3 0 using the following conditions; initial denaturation for 10 min at 951C followed by 30 cycles of 1 min at 941C, 1 min at 521C, and 2 min at 741C with a final extension for 10 min at 721C. The concentration of MgCl 2 , dNTPs, primers and HotStar Taq DNA polymerase used were as for RASSF3. A measure of 1 ml of this reaction was then used in a seminested PCR reaction (50 mls) using CACNA2D2 FN 5 0 -GTTTTTAAAAGGGTTATATATG-TTTTTGTT-3 0 and CACNA2D2 R (described above) and the same PCR program but with 1 U HotStar Taq and 0.8 mM each primer. This produced a 368 bp product. All RASSF3, CACNA2D2, RASSF5 and NORE1B PCR products were assayed for methylation by incubation with TaqI and BstUI for 2 h at 65 and 601C, respectively, before visualization on a 2% agarose gel with added ethidium bromide. The SEMA3B CpG island methylation status was determined by direct sequencing of PCR products obtained using the primers and conditions described in Tomizawa et al. (2001) . The PCR products obtained were purified using the QIAquick PCR Purification Columns (Qiagen -according to manufacturer's instructions), reamplified using ABI BigDye Cycle Sequencing Kit (Perkin Elmer) and analysed using an ABI Prism 377 DNA sequencer (Perkin Elmer).
SssI in vitro methylated (IVM) normal blood DNA was used as a positive control.
LOH analysis
Possible allele loss of CACNA2D2, RASSF1, BLU or SEMA3B was determined using two polymorphic markers from within the 3p21.3 region. D3S1568 and D3S3667 represent the nearest flanking polymorphic loci. Primers used to amplify D3S1568 were 5 0 -AGCAAGGTTTGTCTGT-GAAA-3 0 and 5 0 -GAACCAGCAAGTTCATCAGA-3 0 to produce a product between 276-296 bp. Primers used to amplify D3S3667 were 5 0 -TTTAAGAAGCCTTTGTCA-GAA-3 0 and 5 0 -CTATTGATGTTTCATGGTGC-3 0 to produce a product between 167-183 bp. PCR conditions for both primer pairs were 1.5 mM MgCl 2 , 0.25 mM dNTPs, 0.8 mM each primer, 100 ng DNA and 0.5 U HotStar Taq. The PCR thermocycle for both primer pairs consisted an initial denaturation of 10 min at 951C followed by 35 cycles of 30 s at 951C, 30 s at 501C, 30 s at 721C with a final extension for 10 min at 721C. PCR products were then resolved in a 7% PAGE gel and visualized via silver staining.
Cell lines and 5-aza-2
0 deoxycytidine treatment Glioblastoma cell lines were routinely maintained in RPMI 1640 growth media (Invitrogen) supplemented with 10% FCS at 371C, 5% CO 2 . Cells (5-10 Â 10 5 ) were plated and allowed 24 h growth before addition of 5 mM 5-aza-2 0 -deoxycytidine (Sigma) freshly prepared in ddH 2 0 and filter-sterilized. The medium (including 5 mM 5-aza-2 0 -deoxycytidine) was changed 24 h after seeding and then every 2 days. Controls without 5-aza-2 0 -deoxycytidine were cultured concomitantly in the same manner. RNA was prepared 5 and 7 days after treatment using the RNeasy kit (Qiagen), according to the manufacturer's instructions.
RT-PCR
We analysed the expression of RASSF1A and BLU mRNA in glioblastoma tumor cell lines. RT-PCR was performed using Ready-to-go RT-PCR reaction beads (Amersham Biosciences). Primers and conditions used for RASSF1A RT-PCR were as described in Burbee et al. (2001) . The PCR thermocycle (Hybaid Onm-E) consisted of an initial denaturation of 10 min at 951C followed by 35 cycles of 951C for 30 s, 63.51C for 30 s, 721C for 30 s and a final extension of 10 min at 721C. Primers used for BLU RT-PCR were lung isoform specific with primers located in exon 6.2 (5 0 -GCTTAGCACA-CACAACCTGC-3 0 ) and exon 8 (5 0 -CCTTGGCAAAACTTG TGAGG-3 0 ) to give an expected product size of 233 bp. The PCR thermocycle (Hybaid Onm-E) consisted of an initial denaturation of 10 min at 951C followed by 35 cycles of 951C for 30 s, 581C for 30 s, 721C for 301C and a final extension of 10 min at 721C. Primers used for the GAPDH control were 5 0 -TGAAGGTCGGAGTCAACGGATTTGGT-3 0 and 5 0 -CAT GTGGGCCATGAGGTCCACCAC-3 0 . PCR products were visualized on 2% agarose gel with added ethidium bromide.
Quantitative real-time RT-PCR in primary glioma tumors
The theoretical and practical aspects of real-time quantitative RT-PCR using the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) have been described in detail elsewhere (Bieche et al., 2001) . Briefly, total RNA is reverse-transcribed before real-time PCR amplification. Quantitative values are obtained from the threshold cycle (C t ) number at which the increase in the signal associated with exponential growth of PCR products begins to be detected using PE Biosystems analysis software, according to the manufacturer's manuals. The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e. lack of extensive degradation) are both difficult to assess. We therefore also quantified transcripts of the gene coding for the TATA box-binding protein (TBP) (a component of the DNA-binding protein complex TFIID) as the endogenous RNA control, and each sample was normalized on the basis of its TBP content. Results, expressed as N-fold differences in BLU gene expression relative to the TBP gene, termed NBLU, were determined by the formula: NBLU ¼ 2DC t sample , where DC t value of the sample was determined by subtracting the C t value of the target gene from the C t value of the TBP gene. The nucleotide sequences of the primers used for PCR amplification were: BLU-U (5 0 -GACAGTGTTCTTCCACAAGGAGGT-3 0 ) and BLU-L (5 0 -CAGTTTGCGGTGGCAATAGTCT-3 0 ) with a BLU-specific product size of 82 bp, and TBP-U (5 0 -TGCACAGGAGCCAA GAGTGAA-3 0 ) and TBP-L (5 0 -CACATCACAGCTCCC-CACCA-3 0 ) with a TBP-specific product size of 132 bp. PCR was performed using the SYBR s Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems). To avoid amplification of contaminating genomic DNA, one of the two primers was placed at the junction between two exons. The thermal cycling conditions comprised an initial denaturation step at 951C for 10 min and 50 cycles at 951C for 15 s and 651C for 1 min.
Growth suppression analysis
Glioma cell line H4 (not expressing RASSF1A due to methylation) was used in a colony-formation assay. Using Fugene6 Transfection Reagent (Roche), 2 mg of pCMVHA-RASSF1A mammalian expression construct or pCMVHAempty construct was used to transfect 1 Â 10 5 cells and allowed 48 h for expression of G418 selection marker. At 48 h after transfection, cells were maintained in DMEM-10% fetal bovine serum supplemented with 600 mg geneticin (Sigma). Surviving colonies were counted 14 days later after staining with crystal violet. The experiment was repeated three times.
Statistical analysis
Comparisons were made using Fisher's exact test or w 2 test as appropriate. P-values o0.05 were taken as statistically significant.
